Abstract: Twenty-one patients with Parkinson_s disease were studied before and 2 h after the administration of a single dose of 20 mg of methylphenidate. In response to methylphenidate, attention significantly improved, whereas memory and visualYspatial performance were unchanged. Gait speed, stride time variability, and Timed Up and Go times (demonstrated measures of fall risk) significantly improved. These findings suggest a new potential pharmacologic means of enhancing mobility and decreasing fall risk in Parkinson_s disease.
A lterations in gait and impaired mobility are common among patients with Parkinson_s disease (PD). These motor symptoms often lead to falls and restrict independence. Cognitive changes are also observed in patients with PD. In particular, executive function (EF) and attention abilities seem to be most sensitive to PD; decline in this cognitive domain is reported even among patients with mild disease severity. 1 Attention and EF may be needed for the generation and maintenance of a normal and steady gait pattern, 2, 3 especially in PD. 4 However, the effects of these cognitive changes on motor changes have not been widely studied.
Methylphenidate (MPH) is a central nervous system stimulant derived from amphetamine and works as a potent inhibitor of catecholamine reuptake. 5 MPH is widely used to treat attention deficits in children and adults with attention deficit hyperactivity disorder. Because dopamine reuptake plays an important role in the regulation of dopamine in the synapse, and because the hypodopaminergic state is at the basis of much of the parkinsonian syndrome, it has been suggested that MPH can improve motor function in PD. 6, 7 Given the decline in attention abilities in PD and the putative reliance of a steady gait on this cognitive domain, we hypothesized that MPH may also improve gait and reduce fall risk in patients with PD. In the present pilot open-labeled study, we evaluated the effect of a single dose of MPH on cognitive function, gait performance, and markers of fall risk in 21 patients with PD.
METHODS Subjects
Twenty-one patients with idiopathic PD were enrolled after providing informed consent. Patients with PD treated with L-DOPA with Hoehn and Yahr stages 2Y3 were studied. We excluded patients with motor response fluctuations, psychosis, major depression, dementia according to DSM-IV, Mini Mental State Exam scores G24, uncontrolled hypertension, hepatic or renal failure, uncontrolled malignancy, or untreated glaucoma. Subjects from the outpatient clinic of the Movement Disorders Unit at Tel Aviv Sourasky Medical Center were studied. All patients were diagnosed as having PD by a movement disorders specialist, who applied standard research criteria for PD. In addition, a good response to l-DOPA was obligatory. The study was approved by the institutional review board, and all patients provided informed written consent before participating in the study.
Protocol
The severity of parkinsonism was assessed using the motor part of the Unified Parkinson_s Disease Rating Scale after the subjects took their morning medications. Cognitive function and gait were studied, as described below, before and 2 hours after the administration of a single oral dose of MPH (20 mg). Two hours was chosen because the peak plasma concentration occurs at this time. Because of the potential adrenergic effect of MPH, blood pressure and heart rate were monitored every 30 minutes.
Cognitive Function
Cognitive function was tested using a neuropsychological battery that evaluates multiple domains of cognitive function. The Mindstreams (Neurotrax Corp., NY) cognitive assessment battery 3, 8, 9 was used to quantify indices of attention, EF, memory, handYeye coordination, and visualY spatial abilities using computerized tests based on traditional 
Assessment of Gait and Motor Function
Gait was assessed using footswitches that enable the measurement of gait timing. Previously established measures 2,3 were used to quantify gait speed, stride time, and variability of stride time (using the coefficient of variation) during a 2-minute walk in an obstacle-free, 25-m-long, 2-m-wide hallway. Subjects were asked to walk at their usual pace. We also performed the Timed Up and Go test, in which patients are asked to stand up from a standard chair, walk 3 m, turn around, and return to the seated position. As per standard procedures, the second of 2 trials was used. The Timed Up and Go, gait speed, and stride time variability have been associated with fall risk. 10, 11 To evaluate whether any effects were specific to gait, we also assessed tapping abilities. Participants were instructed to tap on a mouse with their dominant hand for 12 s as quickly as possible. The average intertap interval (ie, time between consecutive taps) and tapping variability (ie, the coefficient of variation) were quantified.
Statistical Analysis
Paired t tests were used to compare gait performance and cognitive function before and after MPH administration (note that similar results were obtained using nonparametric Wilcoxon Signed Rank tests). All P values reported are based on 2-sided comparisons. A P value G0.05 was considered statistically significant. Statistical analyses were performed using SPSS, version 10.
RESULTS
The study population consisted of 18 men and 3 women, with mean age of 70.2 T 9.2 years and 12.5 T 3.4 years of education. Mean Hoehn and Yahr score was 2.0 T 1.0; mean motor Unified Parkinson_s Disease Rating Scale and Mini Mental State Exam scores before MPH administration were 23.0 T 17.0 and 28.8 T 1.7, respectively.
The effects of MPH on cognitive function scores are summarized in Table 1 . In response to MPH treatment, there was a significant increase in the Attention Index (P = 0.025), whereas the Executive Function Index showed a trend towards improvement (P = 0.099). In contrast, scores of memory, visualYspatial orientation, and handYeye coordination were unchanged (P = 0.169).
Measures of gait before and after intake of MPH are shown in Table 2 . Significant improvements were observed for the Timed Up and Go times (P G 0.001), gait speed (P = 0.005), and stride time variability (P = 0.013). Correlations between improvements in cognitive domains and changes (improvements) of gait were not significant. There was no significant improvement in tapping rate or tapping variability (Table 3) . No adverse events were observed.
DISCUSSION
To the best of our knowledge, this is the first study to evaluate the effect of MPH on multiple domains of cognition and gait in patients with PD. The results indicate that a single dose of MPH administrated to patients with PD who receive L-DOPA is associated with a significant improvement in attention and a tendency towards improvement in EF. We also demonstrated a significant improvement in gait speed, stride variability, and Timed Up and Go times, documented markers of abnormal gait and fall risk.
The mechanisms responsible for the observed effects on gait and mobility remain to be more fully determined. MPH may have a widespread effect on parkinsonian symptoms by promoting dopamine uptake in the presence of L-DOPA. In the present study, there was no significant improvement in tapping rate or variability, despite significant changes observed in gait. This suggests that the effects on gait were not simply due to enhanced basal ganglia and dopamine activity in the synapse, in general, but that they were achieved through a more selective effect. We suggest the possibility that MPH worked by enhancing cognitive function. As a result of enhanced attention abilities, relatively complex motor tasks that rely upon attention improved, whereas rhythmic finger tapping, a more simple motor task requiring minimal cognitive input, was not affected. This explanation is consistent with the findings of a previous investigation. 7 In that study, gait speed and a relatively complex hand movement improved in response to MPH in the presence of L-DOPA. However, the lack of an association between the changes in cognitive function and gait in the present study is not fully consistent with this idea. Perhaps, this lack of an association could be the result of confounding factors.
It is important to note that although the effects of MPH on cognitive function, gait, and mobility were significant, the magnitude of the effect was not always very large. Larger and perhaps more consistent effects may be achieved with a higher dose of MPH; for example, 40 mg, twice the dose used here, is considered a safe dose. Future investigations should examine if more robust effects are observed at higher doses. Of course, the trade-offs with respect to side effects are likely to increase, and the costYbenefit ratio needs to be assessed.
Two important limitations need to be considered: practice and the placebo effect. Because a pre-versus posteffect was observed only on specific cognitive and motor tests (eg, there was no change in tests of memory, visualYspatial performances, or tapping), we suggest that any practice or placebo effects were likely minimal. Nonetheless, given the small number of patients and the fact that the present study was an open-label trial, our conclusions are tentative. We suggest that MPH enhances selective aspects of cognitive function, perhaps by its influence on the postsynaptic cleft and presynaptic axon terminals in the central nervous system, and this, in turn, improves gait. The significant effects on attention and gait suggest a novel way of potentially treating gait disturbances and perhaps reducing fall risk in PD, that is, by enhancing cognitive function. Further evaluation in a placebocontrolled, double-blinded study is, however, needed to more fully assess the role of MPH in PD.
